Phase 3Recruiting
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
Sponsored by Xenon Pharmaceuticals Inc.
About this study
X-NOVA3 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants diagnosed with Major Depressive Disorder (MDD)
Enrolling at this location
Delricht Research
Atlanta, Georgia
I'm interestedThis study also enrolls at 34 other locations. See all.
Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.
Trial data sourced from ClinicalTrials.gov.